Alzheimer’s disease: new contrast agents

Publication of the Chemistry Laboratory in the journal Nanomedicine on March 17, 2023. Communication of the CNRS-INC on March 20, 2023. A consortium of European researchers led by two Lyon laboratories - the Chemistry Laboratory (CNRS/ENS de Lyon/Université Claude Bernard Lyon 1) and the Lyon Neuroscience Research Center ( CNRS/Claude Bernard Lyon 1 university/Jean Monnet University/Inserm) - is proposing a new "multi-technique" imaging agent (MRI, X-ray, fluorescence..) targeting amyloid-? (A?) plaques, the first pathological signs of Alzheimer's disease (AD). These results are published in the journal Nanomedicine . The design and study of a new contrast agent targeting amyloid-? (A?) plaques in Alzheimer's disease (AD) is proposed. A? plaques are the earliest pathological sign of AD, silently appearing in the brain decades before the symptoms of the disease are manifested. While current detection of A? plaques is based on nuclear medicine (a technique using a radioactive agent), a different kind of contrast agent is here evaluated in animal models of AD.